Analisis Keuangan Saham QLGN - Qualigen Therapeutics, Inc. (NasdaqCM) Stock

Gambaran Umum

Qualigen Therapeutics, Inc., based in the United States, operates within the biotechnology sector, focusing primarily on developing novel therapeutic products for the treatment of cancer and infectious diseases. The company’s pipeline features several key projects, including QN-247, a DNA-coated gold nanoparticle cancer drug, which is in the preclinical phase aimed at targeting various forms of cancer. Additionally, Qualigen is advancing RAS-F, a family of RAS oncogene protein inhibitors, and ALAN, which is designed to target cancers with their proprietary Fast Pack diagnostic platform. These initiatives showcase Qualigen Therapeutics' commitment to leveraging innovative technologies and complex biochemistry to address critical unmet medical needs in oncology and infectious diseases.

Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih

Nilai operating income untuk Qualigen Therapeutics, Inc. per 2025 Jun 30 adalah -6.18 MM.
Nilai net income untuk Qualigen Therapeutics, Inc. per 2025 Jun 30 adalah -6.98 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-6.18	-6.98
2025-03-31		-6.51	-6.87
2024-12-31		-5.40	-6.26
2024-09-30		-6.70	-7.85
2024-06-30		-8.22	-9.72
2024-03-31		-10.08	-11.60
2023-12-31		-11.30	-13.42
2023-09-30	4.98	-12.47	-17.34
2023-06-30	6.07	-11.86	-17.51
2023-03-31	5.87	-16.63	-18.17
2022-12-31		-14.76	-18.64
2022-09-30	1.48	-15.97	-16.49
2022-06-30	4.79	-18.61	-15.70
2022-03-31	4.48	-21.86	-16.97
2021-12-31	5.65	-22.66	-17.90
2021-09-30	5.28	-22.25	-6.53
2021-06-30	4.96	-21.16	-11.61
2021-03-31	4.75	-16.33	-24.79
2020-12-31	4.31	-11.30	-20.42
2020-09-30	4.59	-6.98	-27.53

Laporan Laba Rugi: EPS

earnings per share basic untuk Qualigen Therapeutics, Inc. pada 2025 Jun 30 adalah -6.50.
laba per saham yang terdilusi untuk Qualigen Therapeutics, Inc. pada 2025 Jun 30 adalah -6.50.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	-6.50	-6.50
2025-03-31	-9.91	-9.91
2024-12-31	-17.55	-17.55
2024-09-30	-41.51	-41.53
2024-06-30	-82.06	-82.07
2024-03-31	-109.64	-109.65
2023-12-31	-132.25	-132.25
2023-09-30	-179.87	-179.71
2023-06-30	-192.65	-192.49
2023-03-31	-216.39	-216.64
2022-12-31	-242.69	-242.79
2022-09-30	-230.99	-229.69
2022-06-30	-237.33	-238.68
2022-03-31	-272.75	-270.73
2021-12-31	-305.05	-305.00
2021-09-30	-119.16	-120.38
2021-06-30	-230.85	-228.56
2021-03-31	-616.18	-618.32
2020-12-31	-705.37	-704.57
2020-09-30	-1,383.01	-1,383.01

Arus Kas: Operasi, Investasi, Pendanaan

Nilai cash from operating activities untuk Qualigen Therapeutics, Inc. per 2025 Jun 30 adalah -6.76 MM.
Nilai cash from investing activities untuk Qualigen Therapeutics, Inc. per 2025 Jun 30 adalah -3.78 MM.
Nilai kas dari aktivitas pendanaan untuk Qualigen Therapeutics, Inc. per 2025 Jun 30 adalah 10.75 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-6.76	-3.78	10.75
2025-03-31	-7.13	-2.21	9.28
2024-12-31	-6.33	-1.91	9.01
2024-09-30	-9.73	-0.66	4.83
2024-06-30	-7.00	4.81	1.07
2024-03-31	-8.45	4.41	-0.07
2023-12-31	-10.30	4.22	-0.55
2023-09-30	-6.87	3.74	2.46
2023-06-30	-10.98	-0.50	2.91
2023-03-31	-12.00	-0.33	2.91
2022-12-31	-13.25	-0.18	2.91
2022-09-30	-13.92	0.04	8.16
2022-06-30	-13.77	0.05	8.28
2022-03-31	-16.53	-0.12	8.32
2021-12-31	-14.73	-0.14	8.43
2021-09-30	-15.27	0.40	12.73
2021-06-30	-16.76	0.22	29.39
2021-03-31	-12.24	-0.13	34.17
2020-12-31	-9.76	-0.16	33.76
2020-09-30	-6.83	-0.69	21.96

Metrik Penilaian: PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31	-0.36	-1.31	-1.31
2024-12-31		-1.41	-1.41
2024-09-30	-0.48	-1.09	-1.09
2024-06-30	-0.08	-0.52	-0.52
2024-03-31		-1.28	-1.28
2023-12-31	-0.16	-1.74	-0.35
2023-09-30	-0.29	1.54	-1.62
2023-06-30	-0.25	0.74	-17.40
2023-03-31	-0.24	0.24
2022-12-31		0.34	1.05
2022-09-30		0.58	1.38
2022-06-30		1.64	1.66
2022-03-31	-2.27	2.16	2.19
2021-12-31	-3.62	3.45	3.51
2021-09-30	-2.42	3.07	3.12
2021-06-30
2021-03-31	-0.60	1.06	1.07
2020-12-31	-0.62	0.89	0.90
2020-09-30	-0.49	-4.65	-3.44

Metrik Penilaian: EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31	-2.02	-3.59
2024-12-31	-1.91	-3.40
2024-09-30	-1.48	-2.51
2024-06-30	-6.29	-8.52
2024-03-31	-24.69	-23.57
2023-12-31	-7.29	-5.56
2023-09-30	-3.03	-2.54
2023-06-30	-6.88	-5.67
2023-03-31	-8.43	-9.83
2022-12-31	-4.75	-5.17
2022-09-30	-2.68	-3.05
2022-06-30	-2.00	-2.05
2022-03-31	-0.93	-1.23
2021-12-31	-0.41	-0.50
2021-09-30	-0.69	-0.66
2021-06-30
2021-03-31	6.08	2.23
2020-12-31	3.38	1.19
2020-09-30	296.52	104.40

Efektivitas Manajemen

roa untuk Qualigen Therapeutics, Inc. pada 2025 Jun 30 adalah 0.00.

Period End (TTM)	ROA	ROE	ROIC (Tingkat Pengembalian Investasi Modal)	CROIC	OCROIC
2025-06-30	0.00
2025-03-31	-3.86
2024-12-31	-3.86
2024-09-30	-2.25
2024-06-30	-0.84	-2.16
2024-03-31	-0.91	-1.98
2023-12-31	-0.76	-1.09	-28.09	-1.09	-11.13
2023-09-30	-0.66	-0.95	-2.69	-1.29	-1.69
2023-06-30	-0.69	-0.98	-2.80	-1.34	-1.76
2023-03-31	-0.88	-1.22	-2.11	-1.07	-1.39
2022-12-31	-1.01	-1.52	-0.90	-0.31	-0.76
2022-09-30	-0.96	-1.45	-0.90	-0.31	-0.76
2022-06-30	-0.85	-1.38	-0.78	-0.27	-0.69
2022-03-31	-0.40	-0.64	-1.12	-0.55	-1.09
2021-12-31	-0.35	-0.56	-0.98	-0.35	-1.71
2021-09-30	-0.50		-0.93	0.52	-1.63
2021-06-30	-1.80		-1.23	1.64	-1.63
2021-03-31	-7.76		-1.49	1.31	-0.96
2020-12-31	-6.36		-1.39	1.69	-0.72
2020-09-30	-6.95

Gross Margins

Margin Kotor: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Margin Keuntungan Bersih: Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.

Margin Operasi: Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.

Period End (TTM)	Margin Kotor	Margin Keuntungan Bersih	Margin Operasi
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30	0.97	-2.69	-2.27
2024-03-31	0.06	-3.48	-3.14
2023-12-31	0.06	-3.48	-3.14
2023-09-30	0.08	-2.89	-2.64
2023-06-30	0.05	-2.89	-2.64
2023-03-31	-0.09	-3.10	-2.83
2022-12-31	-0.09	-3.25	-2.48
2022-09-30	-1.15	-3.25	-2.48
2022-06-30	-0.89	-3.28	-2.72
2022-03-31	-2.14	-3.79	-3.63
2021-12-31	-2.14	-3.17	-3.02
2021-09-30	-2.13	-2.16	-4.92
2021-06-30	-2.13	-3.50	-5.03
2021-03-31	-1.34	-5.22	-3.44
2020-12-31	-0.70	-5.37	-3.31
2020-09-30	-0.20	-6.00	-1.52